APA (7th ed.) Citation

Cella, D., Motzer, R., Rini, B., Cappelleri, J., Ramaswamy, K., Arondekar, B., & Bushmakin, A. (2017). Important Group Differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) in Patients with Metastatic Renal Cell Carcinoma. Value in health, 20(9), A456-A457. https://doi.org/10.1016/j.jval.2017.08.328

Chicago Style (17th ed.) Citation

Cella, D., R. Motzer, BI Rini, JC Cappelleri, K. Ramaswamy, B. Arondekar, and AG Bushmakin. "Important Group Differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) in Patients with Metastatic Renal Cell Carcinoma." Value in Health 20, no. 9 (2017): A456-A457. https://doi.org/10.1016/j.jval.2017.08.328.

MLA (9th ed.) Citation

Cella, D., et al. "Important Group Differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) in Patients with Metastatic Renal Cell Carcinoma." Value in Health, vol. 20, no. 9, 2017, pp. A456-A457, https://doi.org/10.1016/j.jval.2017.08.328.